Previous Close | 47.98 |
Open | 49.42 |
Bid | 0.00 x 900 |
Ask | 0.00 x 800 |
Day's Range | 48.53 - 52.75 |
52 Week Range | 41.33 - 277.80 |
Volume | |
Avg. Volume | 4,621,650 |
Market Cap | 3.923B |
Beta (5Y Monthly) | 1.40 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Novavax, Inc. (NASDAQ: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced its financial results and operational highlights for the first quarter ended March 31, 2022.
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate in BofA Securities 2022 Healthcare Conference. Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced it will report its first quarter 2022 financial results and operational highlights on Monday, May 9, 2022, following the close of U.S. financial markets. Details of the event and replay are as follows: